Check if 3 medicines help advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HLRCC-related kidney cancer OR a confirmed papillary (with “papillary component”) sporadic/non-HLRCC kidney cancer subtype.
- Your kidney cancer is advanced and has at least one tumor spot that can be measured on scans (about 1–2 cm or larger, depending on scan type).
- You’ve had no more than two prior treatments that target the VEGF pathway, and you must not have had bevacizumab for advanced/metastatic disease.
- You must not have had PD-1 or PD-L1 immune medicines (in the metastatic/advanced setting).
- You can do study treatment and tests: age 12+; overall health score ECOG 0–2 (or similar); blood counts and organ/lab numbers are high enough (neutrophils, platelets, liver enzymes, kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
This trial tests whether extra treatment after surgery can help people with a certain type of kidney cancer (stage III papillary kidney cancer) that is at high risk of coming back. The goal is to see if this approach improves outcomes.
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Hear when a new Papillary Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.